Therapeutic Asset Ratings

502 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Rilvegostomig Gastric Cancer	AstraZeneca	P2	CCC (52)
AZD1775 Advanced Solid Tumours	AstraZeneca	P1	CCC (52)
azd2389 Liver Disorder	AstraZeneca	P1	CCC (52)
Inno-206 B-Cell Chronic Lymphocytic Leukemia	AstraZeneca	P1/2	CCC (52)
Itraconazole Ovarian Cancer	AstraZeneca	P2/3	CCC (52)
azd0901 Biliary Tract Cancer	AstraZeneca	P2	CCC (51)
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Biliary Tract Cancer	AstraZeneca	P2	CCC (51)
PREDNISONE TABLETS Biliary Tract Cancer	AstraZeneca	P2	CCC (51)
Vistusertib Non-Small Cell Lung Carcinoma	AstraZeneca	P2	CCC (51)
Volrustomig Biliary Tract Cancer	AstraZeneca	P2	CCC (51)
1H-BENZIMIDAZOLE, 2-(((4-(3-METHOXYPROPOXY)-3-METHYL-2-PYRIDINYL)METHYL)SULFINYL)-, SODIUM SALT, HYDRATE (1:1:1) Prostate Cancer	AstraZeneca	P3	CCC (50)
CALCIUM FOLATE Non-small Cell Lung Cancer	AstraZeneca	P3	CCC (50)
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Colorectal Cancer	AstraZeneca	P2	CCC (50)
Datopotamab Deruxtecan Colorectal Cancer	AstraZeneca	P2	CCC (50)
Datopotamab Deruxtecan Ovarian Cancer	AstraZeneca	P2	CCC (50)
Rilvegostomig Breast Cancer	AstraZeneca	P2	CCC (50)
Rilvegostomig Ovarian Cancer	AstraZeneca	P2	CCC (50)
FLUOROURACILUM Advanced Solid Tumours	AstraZeneca	P1	CCC (50)
PREDNISONE TABLETS B-Cell Chronic Lymphocytic Leukemia	AstraZeneca	P1/2	CCC (50)
azd0901 Gastric Cancer	AstraZeneca	P2	CCC (48)
azd0901 Pancreatic Ductal Adenocarcinoma	AstraZeneca	P2	CCC (48)
AZD1775 Cancer	AstraZeneca	P2	CCC (48)
Ceralasertib Melanoma	AstraZeneca	P2	CCC (48)
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Endometrial Carcinoma	AstraZeneca	P2	CCC (48)
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Gastric Cancer	AstraZeneca	P2	CCC (48)

Showing 151 to 175 of 502 assets

PreviousPage 7 of 21Next